Lemaitre Vascular (LMAT) Cash & Equivalents (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Cash & Equivalents data on file, last reported at $26.9 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $26.9 million, up 5.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.9 million (up 5.96% YoY), and the FY2025 annual result was $28.2 million, up 10.29% from the prior year.
• Cash & Equivalents declined to $26.9 million in Q1 2026 per LMAT's latest filing, from $28.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $28.2 million in Q4 2025 and troughed at $15.6 million in Q1 2022.
• A 5-year average of $22.3 million and a median of $22.3 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents slumped 33.86% in 2022, then jumped 59.47% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $19.1 million in 2022, then rose by 26.84% to $24.3 million in 2023, then grew by 5.53% to $25.6 million in 2024, then advanced by 10.29% to $28.2 million in 2025, then retreated by 4.93% to $26.9 million in 2026.
• Business Quant data shows LMAT's Cash & Equivalents at $26.9 million in Q1 2026, $28.2 million in Q4 2025, and $25.5 million in Q3 2025.